Cover Image
市場調查報告書

神經性疼痛:開發中產品分析

Neuropathic Pain - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 232786
出版日期 內容資訊 英文 572 Pages
訂單完成後即時交付
價格
Back to Top
神經性疼痛:開發中產品分析 Neuropathic Pain - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 572 Pages
簡介

神經性疼痛,或是神經痛是指感覺系統收到的狀態,一般伴隨組織障礙。神經線維損傷的話會發生異常信號。神經性疼痛與其他疾病一起發生。症侯從電擊痛到沒有感覺。 雖然引起疼痛的原因有好幾個,但是沒有特定的原因。身體的外傷、腎臟病、酒精成癮(酒精中毒)、感染疾病、壓力等也與疼痛的症狀相連。治療以藥物療法和心理治療來緩和症狀。

本報告提供神經性疼痛的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

神經性疼痛概要

治療藥的開發

神經性疼痛:企業開發中的治療藥

神經性疼痛:大學/機關研究中的治療藥

神經性疼痛:開發中產品概況

神經性疼痛:企業開發中的產品

神經性疼痛:大學/機關研究中的產品

神經性疼痛的治療藥開發作的企業

神經性疼痛:治療藥的評估

藥物簡介

神經性疼痛:暫停中的計劃

神經性疼痛:開發中止的產品

神經性疼痛:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7966IDB

Summary

Global Markets Direct's, 'Neuropathic Pain - Pipeline Review, H1 2016', provides an overview of the Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
  • The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects
  • The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neuropathic Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Neuropathic Pain Overview
  • Therapeutics Development
  • Neuropathic Pain - Therapeutics under Development by Companies
  • Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
  • Neuropathic Pain - Pipeline Products Glance
  • Neuropathic Pain - Products under Development by Companies
  • Neuropathic Pain - Products under Investigation by Universities/Institutes
  • Neuropathic Pain - Companies Involved in Therapeutics Development
  • Neuropathic Pain - Therapeutics Assessment
  • Drug Profiles
  • Neuropathic Pain - Dormant Projects
  • Neuropathic Pain - Discontinued Products
  • Neuropathic Pain - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Neuropathic Pain, H1 2016
  • Number of Products under Development for Neuropathic Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H1 2016
  • Neuropathic Pain - Pipeline by AbbVie Inc., H1 2016
  • Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Adynxx, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Aestus Therapeutics, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H1 2016
  • Neuropathic Pain - Pipeline by Amura Holdings Limited, H1 2016
  • Neuropathic Pain - Pipeline by AnaBios Corporation, H1 2016
  • Neuropathic Pain - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Neuropathic Pain - Pipeline by AngioChem Inc., H1 2016
  • Neuropathic Pain - Pipeline by APT Therapeutics, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Arena Pharmaceuticals, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp., H1 2016
  • Neuropathic Pain - Pipeline by Astellas Pharma Inc., H1 2016
  • Neuropathic Pain - Pipeline by AstraZeneca Plc, H1 2016
  • Neuropathic Pain - Pipeline by BCI Pharma, H1 2016
  • Neuropathic Pain - Pipeline by BCN Peptides, S.A., H1 2016
  • Neuropathic Pain - Pipeline by Benitec Biopharma Limited, H1 2016
  • Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Biogen, Inc., H1 2016
  • Neuropathic Pain - Pipeline by BioLineRx, Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Biomar Microbial Technologies, H1 2016
  • Neuropathic Pain - Pipeline by Bionomics Limited, H1 2016
  • Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Cara Therapeutics, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Catalyst Biosciences, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Cavion LLC, H1 2016
  • Neuropathic Pain - Pipeline by Centrexion Corporation, H1 2016
  • Neuropathic Pain - Pipeline by Cerecor Inc., H1 2016
  • Neuropathic Pain - Pipeline by Chromocell Corporation, H1 2016
  • Neuropathic Pain - Pipeline by Circuit Therapeutics, Inc., H1 2016
  • Neuropathic Pain - Pipeline by CLL Pharma, H1 2016
  • Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H1 2016
  • Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Creabilis SA, H1 2016
  • Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Cytogel Pharma, LLC, H1 2016
  • Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Neuropathic Pain - Pipeline by DermaXon, LLC, H1 2016
  • Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H1 2016
  • Neuropathic Pain - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Neuropathic Pain - Pipeline by Eisai Co., Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2016
  • Neuropathic Pain - Pipeline by Endece, LLC, H1 2016
  • Neuropathic Pain - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Genecode AS, H1 2016
  • Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Glialogix, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Grunenthal GmbH, H1 2016
  • Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H1 2016
  • Neuropathic Pain - Pipeline by Integral Molecular, Inc., H1 2016
  • Neuropathic Pain - Pipeline by IntelGenx Corp., H1 2016
  • Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc., H1 2016
  • Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Johnson & Johnson, H1 2016
  • Neuropathic Pain - Pipeline by Kareus Therapeutics, SA, H1 2016
  • Neuropathic Pain - Pipeline by Kineta, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H1 2016
  • Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016
  • Neuropathic Pain - Pipeline by LEO Pharma A/S, H1 2016
  • Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Lipopharma Therapeutics SL, H1 2016
  • Neuropathic Pain - Pipeline by Lohocla Research Corporation, H1 2016
  • Neuropathic Pain - Pipeline by Lpath, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Mapi Pharma Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Neuropathic Pain - Pipeline by Medisyn Technologies, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Medy-Tox Inc., H1 2016
  • Neuropathic Pain - Pipeline by Merck & Co., Inc., H1 2016
  • Neuropathic Pain - Pipeline by Nanomerics Ltd, H1 2016
  • Neuropathic Pain - Pipeline by Nektar Therapeutics, H1 2016
  • Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016
  • Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Neurodyn Inc., H1 2016
  • Neuropathic Pain - Pipeline by NeurOp, Inc, H1 2016
  • Neuropathic Pain - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016
  • Neuropathic Pain - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016
  • Neuropathic Pain - Pipeline by NoNO, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Novaremed, H1 2016
  • Neuropathic Pain - Pipeline by Novartis AG, H1 2016
  • Neuropathic Pain - Pipeline by NsGene A/S, H1 2016
  • Neuropathic Pain - Pipeline by Orion Oyj, H1 2016
  • Neuropathic Pain - Pipeline by PeriphaGen, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Pfizer Inc., H1 2016
  • Neuropathic Pain - Pipeline by Pharmaleads SA, H1 2016
  • Neuropathic Pain - Pipeline by PharmEste, H1 2016
  • Neuropathic Pain - Pipeline by Phosphagenics Limited, H1 2016
  • Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H1 2016
  • Neuropathic Pain - Pipeline by RaQualia Pharma Inc., H1 2016
  • Neuropathic Pain - Pipeline by Re-Pharm Limited, H1 2016
  • Neuropathic Pain - Pipeline by Recro Pharma, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Revance Therapeutics, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Saniona AB, H1 2016
  • Neuropathic Pain - Pipeline by Scilex Pharmaceuticals, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Spherium Biomed S.L., H1 2016
  • Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016
  • Neuropathic Pain - Pipeline by Syntrix Biosystems, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Theranexus SAS, H1 2016
  • Neuropathic Pain - Pipeline by Theravasc, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Toray Industries, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Limited, H1 2016
  • Neuropathic Pain - Pipeline by Trevena, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Trigemina, Inc., H1 2016
  • Neuropathic Pain - Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Virobay Inc., H1 2016
  • Neuropathic Pain - Pipeline by VistaGen Therapeutics , Inc., H1 2016
  • Neuropathic Pain - Pipeline by Yuhan Corporation, H1 2016
  • Neuropathic Pain - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Neuropathic Pain - Dormant Projects, H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..1), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..2), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..3), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..4), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..5), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..6), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..7), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..8), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..9), H1 2016
  • Neuropathic Pain - Dormant Projects (Contd..10), H1 2016

List of Figures

  • Number of Products under Development for Neuropathic Pain, H1 2016
  • Number of Products under Development for Neuropathic Pain - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top